May 12, 2022
Article
A significantly greater proportion or patients treated with either 15 or 30 mg show remission or endoscopic response or remission at week 52 compared with the placebo.
May 10, 2022
Vedolizumab (Entyvio) is indicated for adult patients with moderately to severely active ulcerative colitis and adult patients with moderately to severely active Crohn disease.
April 13, 2022
Offer suggestions for nonprescription products when appropriate, but urge consultation with health care providers if self-treatment is not advisable.
April 11, 2022
Inflammatory bowel disease has complex treatment options, but pharmacists can help patients make the right choice.
April 01, 2022
Podcast
There is more to patients with IBD than the physical detriments, with many mental health issues arising from the condition.
March 31, 2022
Golytely is indicated for cleansing of the colon in preparation for colonoscopy and barium enema X-ray examination in adults.
March 29, 2022
The drug met the co-primary endpoints of clinical remission at both weeks 12 and 52 and all key secondary endpoints in the study.
March 17, 2022
Patients treated with upadacitinib achieved clinical remission of ulcerative colitis more frequently through weeks 8 and 52 versus the placebo group.
January 31, 2022
Mesalamine (Apriso) is a locally acting aminosalicylate indicated to treat and prevent flare-ups of ulcerative colitis.
January 27, 2022
Linaclotide (Linzess) is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation.
